Page 30 - Read Online
P. 30

Page 14 of 16                                        Cidon. J Unexplored Med Data 2018;3:8  I  http://dx.doi.org/10.20517/2572-8180.2018.03

               Financial support and sponsorship
               None.


               Conflicts of interest
               The author declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2018.



               REFERENCES
               1.   Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
               2.   Siegel RL, Miller KD, Jemal A. Cancer stastistics, 2017. CA Cancer J Clin 2017;67:7-30.
               3.   Foubert F, Matysiak-Budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis
                   2014;46:105-12.
               4.   Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
               5.   Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. Open-label phase III trial of panitumumab plus best supportive
                   care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol
                   2007;25:1658-64.
               6.   Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. Genetic alterations during colorectal-tumor development. N Engl J
                   Med 1988;319:525-32.
               7.   Novellasdemunt L, Antas P, Li VS. Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: proteins, pathways
                   and mechanisms. Am J Physiol Cell Physiol 2015;309:C511-21.
               8.   Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, et al. Prevalence of RAS mutations and individual variation patterns among
                   patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur J Cancer 2015;51:1704-13.
               9.   Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-
                   line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label,
                   phase 3 TRIBE study. Lancet Oncol 2015;16:1306-15.
               10.  Richman SD, Southward K, Chambers P, Cross D, Barrett J, et al. HER2 overexpression and amplification as a potential therapeutic
                   target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol
                   2016;238:562-70.
               11.  Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004;23:11-27.
               12.  Grady WM, Markowitz S. Genomic instability and colorectal cancer. Curr Opin Gastroenterol 2000;16:62-7.
               13.  Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis
                   colorectal cancer (HNPCC). Cancer Res 2001;61:4545-9.
               14.  Gausachs M, Mur P, Corral J, Pineda M, González S, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch
                   syndrome: a cost-effectiveness study. Eur J Hum Genet 2012;20:762-8.
               15.  Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138:2059-72.
               16.  Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, et al. Signatures of mutational processes in human cancer. Nature
                   2013;500:415-21.
               17.  Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, et al. Prognosis of stage II and III colon cancer treated with adjuvant
                   5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015;26:126-32.
               18.  Guerra J, Pinto C, Pinto D, Pinheiro M, Silva R et al. POLE somatic mutations in advanced colorectal cancer. Cancer Med 2017;6:2966-
                   71.
               19.  Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, et al. The consensus molecular subtypes of colorectal cancer. Nat Med
                   2015;21:1350-6.
               20.  Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A
                   in cancer patients. Nature 2014;515:563-7.
               21.  Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s
                   lymphoma. N Engl J Med 2015;372:311-9.
               22.  Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl
                   J Med 2013;369:134-44.
               23.  Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, et al. PD-L1 regulates the development, maintenance, and function of
   25   26   27   28   29   30   31   32   33   34   35